Form 4: Zevra Therapeutics CFO Acquires 2,000 Shares of Common Stock
SEC Form 4 Filing
R. LaDuane Clifton, CFO & Treasurer of Zevra Therapeutics, recently purchased 2,000 shares of the company's common stock at a price of $6.77 per share.
Summary
- On July 17, 2024, R. LaDuane Clifton, the CFO & Treasurer of Zevra Therapeutics, Inc., acquired 2,000 shares of common stock.
- The purchase price was $6.77 per share.
- Following the transaction, Clifton directly owns 18,469 shares of Zevra Therapeutics common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral. It's a routine disclosure of an insider stock purchase. While insider buying can be seen as a positive signal, it's a single transaction and doesn't provide definitive insight into the company's overall health.
Positives
- The CFO's purchase of company stock could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders. Investors often monitor these filings to gain insights into management's perspective on the company's valuation and future prospects.
Key Dates
| Date | Description |
|---|---|
| 07/17/2024 | Date of transaction: R. LaDuane Clifton purchased 2,000 shares of Zevra Therapeutics common stock. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.